Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
TTI-101 was well tolerated. cPRs were observed across tumor types. The antitumor activity of TTI-101 monotherapy in patients with advanced, metastatic solid tumors is promising. A phase II study of TTI-101 in hepatocellular carcinoma is currently underway.
Authors
- Rony Avritscher (ORCID: https://orcid.org/0000-0002-5122-3445)
- Apostolia M. Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- Ahmed Omar Kaseb (ORCID: https://orcid.org/0000-0002-9491-0587)
- Sofia de Achaval
- David Vining
- John Kauh (ORCID: https://orcid.org/0000-0002-4359-7383)
- Sukeshi Patel Arora (ORCID: https://orcid.org/0000-0002-1176-0713)
- Imran Alibhai
- David J. Tweardy (ORCID: https://orcid.org/0000-0001-8492-8460)
- Carrie Cartwright
- Jeffrey Larson
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Mirna Therapeutics (United States) (US)
- Houston Methodist Sugar Land Hospital (US)
- Mays Cancer Center at UT Health San Antonio (US)
- Anderson University - South Carolina (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2920
- Citations
- 31
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 24.99
Funders
- Pfizer
- AstraZeneca
- Boston Scientific Corporation
- Exelixis
- Novocure
- Parker Institute for Cancer Immunotherapy
- BeiGene
- Actuate Therapeutics
- MacroGenics
- Seagen
- Eisai
- National Institutes of Health
- Genentech
- University of Texas MD Anderson Cancer Center
- National Cancer Institute